KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Debt (2016 - 2025)

Historic Total Debt for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $1.6 billion.

  • BeOne Medicines' Total Debt rose 5657.05% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 5657.05%. This contributed to the annual value of $1.0 billion for FY2024, which is 1490.2% up from last year.
  • As of Q3 2025, BeOne Medicines' Total Debt stood at $1.6 billion, which was up 5657.05% from $954.5 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Total Debt ranged from a high of $1.6 billion in Q3 2025 and a low of $488.1 million during Q1 2023
  • Moreover, its 5-year median value for Total Debt was $643.3 million (2021), whereas its average is $790.6 million.
  • Its Total Debt has fluctuated over the past 5 years, first soared by 28463.44% in 2021, then plummeted by 1985.02% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Total Debt stood at $629.7 million in 2021, then fell by 19.48% to $507.0 million in 2022, then skyrocketed by 74.74% to $886.0 million in 2023, then rose by 14.9% to $1.0 billion in 2024, then surged by 61.69% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q3 2025, $954.5 million for Q2 2025, and $923.6 million during Q1 2025.